Korro Bio, Inc.
NasdaqCM KRRO
Korro Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00
Korro Bio, Inc. Revenue Per Share is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
-
Korro Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
-
Korro Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a -100.00% change year over year.
-
Korro Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 35.16, a -30.29% change year over year.
-
Korro Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 50.44.
Key data
| Date | Revenue Per Share | Dividend Per Share | Free Cash Flow Per Share | Return on Assets (ROA) |
|---|
Market news
Loading...
Don’t Miss A Beat
NasdaqCM: KRRO
| CEO | Mr. Ram Aiyar MBA, Ph.D. |
| IPO Date | Oct. 3, 2019 |
| Location | United States |
| Headquarters | One Kendall Square |
| Employees | 101 |
| Sector | Healthcare |
| Industries | |
Description
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Key trends
Past 5 years
StockViz Staff
February 4, 2025
Any question? Send us an email